| The ubiquitin E3 ligase activity of BRCA1 and its biological functions W Wu, A Koike, T Takeshita, T Ohta Cell division 3, 1-10, 2008 | 158 | 2008 |
| Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence A Sueta, Y Yamamoto, M Tomiguchi, T Takeshita, M Yamamoto-Ibusuki, ... Oncotarget 8 (41), 69934, 2017 | 132 | 2017 |
| Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens T Takeshita, Y Yamamoto, M Yamamoto-Ibusuki, T Inao, A Sueta, ... Translational Research 166 (6), 540-553. e2, 2015 | 86 | 2015 |
| Prognostic role of PIK3CA mutations of cell‐free DNA in early‐stage triple negative breast cancer T Takeshita, Y Yamamoto, M Yamamoto‐Ibusuki, T Inao, A Sueta, ... Cancer science 106 (11), 1582-1589, 2015 | 77 | 2015 |
| Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients T Takeshita, Y Yamamoto, M Yamamoto-Ibusuki, T Inao, A Sueta, ... Oncotarget 7 (22), 32504, 2016 | 67 | 2016 |
| Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients T Takeshita, Y Yamamoto, M Yamamoto-Ibusuki, M Tomiguchi, A Sueta, ... Oncotarget 8 (32), 52142, 2017 | 65 | 2017 |
| Late recurrence of breast cancer is associated with pro-cancerous immune microenvironment in the primary tumor T Takeshita, L Yan, M Asaoka, O Rashid, K Takabe Scientific reports 9 (1), 16942, 2019 | 59 | 2019 |
| Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer T Takeshita, Y Yamamoto, M Yamamoto-Ibusuki, M Tomiguchi, A Sueta, ... Molecular cancer 17, 1-6, 2018 | 59 | 2018 |
| High expression of polo-like kinase 1 is associated with TP53 inactivation, DNA repair deficiency, and worse prognosis in ER positive Her2 negative breast cancer T Takeshita, M Asaoka, E Katsuta, SJ Photiadis, S Narayanan, L Yan, ... American journal of translational research 11 (10), 6507, 2019 | 53 | 2019 |
| Fibroblast growth factor receptor‐1 protein expression is associated with prognosis in estrogen receptor‐positive/human epidermal growth factor receptor‐2‐negative primary … M Tomiguchi, Y Yamamoto, M Yamamoto‐Ibusuki, L Goto‐Yamaguchi, ... Cancer science 107 (4), 491-498, 2016 | 51 | 2016 |
| High MYC mRNA expression is more clinically relevant than MYC DNA amplification in triple-negative breast cancer E Katsuta, L Yan, T Takeshita, KA McDonald, S Dasgupta, M Opyrchal, ... International journal of molecular sciences 21 (1), 217, 2019 | 43 | 2019 |
| C6ORF97-ESR1 breast cancer susceptibility locus: influence on progression and survival in breast cancer patients M Yamamoto-Ibusuki, Y Yamamoto, S Fujiwara, A Sueta, S Yamamoto, ... European Journal of Human Genetics 23 (7), 949-956, 2015 | 38 | 2015 |
| Comparison of ESR1 mutations in tumor tissue and matched plasma samples from metastatic breast cancer patients T Takeshita, Y Yamamoto, M Yamamoto-Ibusuki, M Tomiguchi, A Sueta, ... Translational Oncology 10 (5), 766-771, 2017 | 37 | 2017 |
| Lenvatinib, an oral multi-kinases inhibitor,-associated hypertension: Potential role of vascular endothelial dysfunction D Sueta, K Suyama, A Sueta, N Tabata, T Yamashita, M Tomiguchi, ... Atherosclerosis 260, 116-120, 2017 | 36 | 2017 |
| An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer A Sueta, Y Yamamoto, M Yamamoto-Ibusuki, M Hayashi, T Takeshita, ... PLoS One 9 (12), e116054, 2014 | 36 | 2014 |
| The localization of HER4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER+ HER2-breast cancer S Fujiwara, M Yamamoto-Ibusuk, Y Yamamoto, S Yamamoto, ... Oncotarget 5 (11), 3919, 2014 | 36 | 2014 |
| Perturbation of DNA repair pathways by proteasome inhibitors corresponds to enhanced chemosensitivity of cells to DNA damage-inducing agents T Takeshita, W Wu, A Koike, M Fukuda, T Ohta Cancer chemotherapy and pharmacology 64, 1039-1046, 2009 | 29 | 2009 |
| Therapeutic predictors of neoadjuvant endocrine therapy response in estrogen receptor-positive breast cancer with reference to optimal gene expression profiling L Goto-Yamaguchi, M Yamamoto-Ibusuki, Y Yamamoto, Y Fujiki, ... Breast cancer research and treatment 172, 353-362, 2018 | 28 | 2018 |
| Differential role of MACC1 expression and its regulation of the HGF/c‑Met pathway between breast and colorectal cancer A Sueta, Y Yamamoto, M Yamamoto‑Ibusuki, M Hayashi, T Takeshita, ... International journal of oncology 46 (5), 2143-2153, 2015 | 23 | 2015 |
| Clinical implications of occult metastases and isolated tumor cells in sentinel and non-sentinel lymph nodes in early breast cancer patients: serial step section analysis with … T Takeshita, H Tsuda, T Moriya, T Yamasaki, H Asakawa, S Ueda, K Sato, ... Annals of surgical oncology 19, 1160-1166, 2012 | 21 | 2012 |
